Special Issue "Alzheimer’s Disease: Small-Molecule Modulators of Novel Therapeutic Pathways"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 1222
Interests: Alzheimer's disease; cancer; metabolic engineering; interactome engineering
Special Issues, Collections and Topics in MDPI journals
After more than a century since Dr. Alois Alzheimer, a German physician, described the first Alzheimer’s disease (AD) case in 1906, AD still remains a daunting medical and socio-economical challenge.
AD is an age-related, progressive neurodegenerative disease, clinically characterized by severe memory loss and impairment of various cognitive functions. Pathologically, AD is characterized by extracellular deposits of amyloid beta (Aβ) protein and intracellular accumulation of neurofibrillary tangles of tau (τ) protein. Accordingly, much of the therapeutic focus has been on the Aβ plaques and τ tangles. Recently, two anti-amyloid antibodies targeting aggregated (Aducanumab) and protofibril (Lecanemab) forms of Aβ have been approved by the FDA, but with only small clinical benefits. On the small-molecule side, four acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine, and tacrine) and one NMDA receptor antagonist (memantine) are in clinical use, providing only limited and symptomatic effects. Thus, there is a significant unmet need for investigating novel disease mechanisms, leading to the discovery and development of disease-modifying drugs against this devastating disease.
This Special Issue is dedicated to gathering such novel AD mechanisms, with a particular emphasis on targeting these mechanisms using small-molecule drugs. These drugs may offer several benefits versus large biotherapeutics, such as low cost and relatively easier delivery to brain. In addition to the de novo drug discovery efforts, the drug repurposing/repositioning studies that involve approved/investigational drugs are also particularly welcome.
We look forward to your contribution to this Special Issue, in the form of original research articles or focused reviews.
Dr. Sachin P. Patil
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer’s disease
- small molecules
- disease mechanisms
- drug discovery and design